Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis of cell proliferation: validation of a simplified method suitable for multi-center clinical studies.
Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis of cell proliferation: validation of a simplified method suitable for multi-center clinical studies.
复制标题
从慢性淋巴细胞性白血病（CLL）患者中分离出恶性B细胞，以分析细胞增殖：验证一种适合多中心临床研究的简化方法。
DOI：
10.1016/j.leukres.2009.09.032
复制
发表时间：
2010-06
影响因子：
2.7
通讯作者：
Murphy EJ
中科院分区：
文献类型：
--
作者：
Hayes GM;Busch R;Voogt J;Siah IM;Gee TA;Hellerstein MK;Chiorazzi N;Rai KR;Murphy EJ
Heavy water (2H2O) labelling of DNA enables the measurement of low-level cell proliferation in vivo, using gas chromatography/pyrolysis isotope ratio mass spectrometry (GC/P/IRMS), but the methodology has been too complex for widespread use. Here, we report a simplified method for measuring proliferation of malignant B cells in patients with chronic lymphocytic leukemia (CLL). Patients were labelled with 2H2O for 6 weeks; blood samples were obtained at 0, 3, and 6 weeks during 2H2O labelling and 9, 12, and 16 weeks thereafter. Bone marrow was sampled at week 6. Phlebotomy was performed at multiple, non-research clinical sites. CLL cells were isolated in a central laboratory, using a novel RosetteSep™-based method; DNA labelling was analysed by GC/P/IRMS. In 26 of 29 patients, CLL cell isolation resulted in ≥ 95% purity for malignant CD5+ B cells; in one patient, malignant cells expressed marginal levels of CD5, and in two others, further sorting of CD5hi malignant cells was required. Cell yields correlated with white blood cell counts and exceeded GC/P/IRMS requirements (≈ 107 cells) > 98% of the time; high-quality DNA labelling data were obtained. RosetteSep isolation achieved adequate CLL cell purity from bone marrow in only 64% of samples, but greatly reduced subsequent sort time for impure samples. This method enables clinical studies of CLL cell proliferation outside of research settings, using a shorter 2H2O intake protocol, a minimal sampling protocol, and centralised sample processing. The CLL cell isolation protocol may also prove useful in other applications. (clinicaltrials.gov identifier: NCT00481858)
